An experimental treatment against ‘certain death’

Healthed

writer

Healthed

Healthed

It is risky and untested treatment. It could shorten his life or make it a whole lot worse. But it’s a risk Professor Richard Scolyer is willing to take, desperate to try and save his own life. As the world’s top melanoma pathologist, Richard is an expert in diagnosing skin cancers, and helped revolutionise immunotherapy treatment for advanced melanoma patients, removing the death sentence so many once faced. But now the acclaimed doctor is facing his own mortality. Richard had a choice, prepare for the worst or put his hand up to be patient zero as his colleagues design a high stakes experiment to fight his brain tumour, using the very treatment they have pioneered for melanoma.

 

 

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Andrew Leech

Dr Andrew Leech

Managing Paediatric Anxiety in General Practice

Prof Brendon Yee

Prof Brendon Yee

OSA – Which Test for Which Patient

Dr Sonia Davison

Dr Sonia Davison

Musculoskeletal Health in Menopause

Mr David Gardner

Mr David Gardner

AHPRA-Proof Your Practice – Social Media Risks for GPs

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Healthed

writer

Healthed

Test your knowledge

Recent articles

Latest GP poll

How much do you agree or disagree that the current checks and balances on AHPRA's powers need improvement?

Strongly agree

0%

Somewhat agree

0%

Neutral

0%

Somewhat disagree

0%

strongly disagree

0%

Recent podcasts

Listen to expert interviews.
Click to open in a new tab

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease